LianBio Announces Departure of Chief Financial Officer
20 Dezember 2023 - 2:00PM
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to
bringing innovative medicines to patients in China and other major
Asian markets, today announced that Yi Larson, Chief Financial
Officer, has resigned from LianBio to pursue other opportunities,
effective December 19, 2023.
In connection with her departure, the LianBio Board of Directors
has appointed Ehong (Maggie) Gu, current VP, Head of Global
Finance, as Interim Chief Financial Officer.
“We are grateful to Yi for her many contributions to strategic
initiatives at LianBio and wish her continued success in her next
role,” said Konstantin Poukalov, Executive Chairman of the LianBio
Board of Directors.
About LianBioLianBio is a cross-border
biotechnology company on a mission to bring transformative
medicines to patients in China and other Asian markets. Through
partnerships with highly innovative biopharmaceutical companies
around the world, LianBio is advancing a diversified portfolio of
clinically validated product candidates with the potential to drive
new standards of care across oncology, ophthalmology, inflammatory
disease and respiratory indications. LianBio is establishing an
international infrastructure to position the company as a partner
of choice with a platform to provide access to China and other
Asian markets. For additional information, please visit the
company’s website at www.lianbio.com.
For investor inquiries, please
contact:Elizabeth Anderson, VP Communications and Investor
RelationsE: elizabeth.anderson@lianbio.com T: (646) 655-8390
For media inquiries, please contact: Katherine
Smith, Evoke CanaleE: katherine.smith@evokegroup.com T: (619)
849-5378
LianBio (NASDAQ:LIAN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
LianBio (NASDAQ:LIAN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024